The GYG1 Knockout Jurkat Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat human T lymphocytes, engineered to disrupt the GYG1 gene. This gene-edited pool offers a loss-of-function model for studying glycogenin-1 in a well-characterized T-cell context. The polyclonal nature provides a heterogeneous knockout population suitable for downstream assays without clonal selection bottlenecks.
Jurkat cells are an immortalized T lymphoblast line established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Widely utilized as a model for T-cell receptor signaling, apoptosis, and HIV replication, Jurkat cells exhibit robust IL-2 production and are a standard platform for immunological and cancer research. Their leukemic origin and metabolic plasticity make them particularly valuable for dissecting pathways that intersect with cell proliferation and survival.
Glycogenin-1 (GYG1) is a glycosyltransferase responsible for autoglucosylation to generate a short glucose oligomer that serves as an essential primer for glycogen biosynthesis. This process is tightly regulated by insulin signaling, glucose availability, and the kinase AKT. Following primer formation, glycogen synthase 1 (GYS1) and glycogen branching enzyme (GBE1) elongate and branch the polyglucose chain to form mature glycogen particles. GYG1 also homodimerizes and physically interacts with GYS1 and GBE1, positioning it at the initiation core of glycogen particles. Targeted disruption of GYG1 abolishes primer formation, thereby preventing glycogen accumulation and perturbing metabolic networks that depend on glycogen turnover.
In Jurkat T lymphocytes, glycogen serves as a carbon and energy reservoir, contributing to metabolic flexibility during activation and proliferation. GYG1 knockout in this setting eliminates the cell’s capacity for de novo glycogen synthesis, likely forcing a reliance on alternative fuel sources such as glutamine or fatty acids. This model recapitulates aspects of glycogen storage disease type XV, wherein GYG1 mutations lead to glycogen depletion in skeletal and cardiac muscle. The Jurkat-based knockout thus provides a tractable system to explore the role of glycogen metabolism in leukemic T cells and its impact on signaling pathways sensitive to redox or energy status.
Typical applications include immunoblotting to confirm GYG1 protein loss, periodic acid?CSchiff (PAS) staining for glycogen visualization, and metabolic flux analysis using Seahorse technology to assess glycolytic and mitochondrial function. The polyclonal population is also suitable for glucose uptake assays, RT-qPCR profiling of glycogen metabolism genes, and flow cytometry-based analyses of viability, apoptosis, or proliferation. By combining efficient gene disruption with a well-established T-cell model, these cells facilitate investigations into metabolic reprogramming, T-cell activation, and glycogen-related pathologies. For further technical information, please contact Ascent Research.
